A top human resources officer at Eli Lilly and Co.’s factory in New Jersey claims the drugmaker fired her in retaliation for investigating employee complaints about drug manufacturing problems and for refusing to drop the matter.
Researchers in the field of colorectal cancer are hailing the study, published Sunday in the New England Journal of Medicine, as a groundbreaking development that could lead to new treatments for other cancers as well.
The Attorney General’s office reported all 648 political subdivisions in Indiana have joined the settlement, which is part of a roughly $26 billion payout across 46 states.
Novavax shots are already used in Australia, Canada, parts of Europe and dozens of other countries. But U.S. clearance is a key hurdle for the Maryland-based company.
Germany-based Evonik announced Thursday that it will expand its pharmaceutical production facility in Lafayette. The plant will build produce lipids for mRNA-based therapies in the United States.
The Indianapolis-based drugmaker said Wednesday the project in Boone County will create up to 500 jobs in central Indiana, along with up to 1,500 temporary construction jobs.
The drug has been closely watched by medical professionals and is viewed by financial analysts as a possible blockbuster, with potential annual sales in the billions of dollars.
The pharmaceutical giant is turning heads with an experimental medicine it claims can help obese patients shed nearly a quarter of their body weight and manage diabetes.
A panel of Indiana life science experts on Friday said the state could become more competitive for large investments and jobs if it doubled down on the kind of collaborations and partnerships that other states have used to their advantage.
Eli Lilly and Co. posted profit of $1.9 billion in the first quarter, up 40%, on higher sales of COVID-19 antibodies and other key products for diabetes, cancer and arthritis.
Moderna on Thursday asked U.S. regulators to authorize low doses of its COVID-19 vaccine for children younger than 6, a long-awaited move toward potentially opening shots for millions of tots by summer.
The drug, called tirzepatide, has been closely watched by medical professionals and is viewed by financial analysts as possible blockbuster, with potential annual sales in the billions of dollars.
Paxlovid, when administered within five days of symptoms appearing, has been proven to bring about a 90% reduction in hospitalizations and deaths among patients most likely to get severe disease.
COVID-19 vaccinations are at a critical juncture as companies test whether new approaches like combination shots or nasal drops can keep up with a mutating coronavirus—even though it’s not clear if changes are needed.
The imaging agent is the six-year-old company’s first commercial launch, following millions of dollars’ worth of research and clinical tests. It was approved by the U.S. Food and Drug Administration in December.
The expansion comes on top of more than 1,000 positions the drugmaker has added since Jan. 1, 2021, bringing its current Bloomington workforce total to more than 4,000, which includes employees and workers provided by staffing agencies.
Moderna hopes to offer updated COVID-19 boosters in the fall that combine its original vaccine with protection against the omicron variant.
Acacia Pharma Group employees are waiting to see what will happen to their jobs and whether the company will remain in Indianapolis in any form, now that it is being acquired by New Jersey-based specialty drugmaker Eagle Pharmaceuticals Inc. for $103.9 million.
The push by Eli Lilly and Co. will come despite an unfavorable ruling last week from Medicare that sharply restricts reimbursements for a drug in the same class.
Thursday’s coverage decision illustrates the impact that a single medication can have on the budgets of individuals and taxpayers.
